Sera Prognostics(US:SERA)2026-03-18 22:00Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $10,000, down from $24,000 in Q4 2024, reflecting modest revenue fluctuations typical in early commercial stages [19] - Total revenue for 2025 was $81,000, a slight increase from $77,000 in 2024, indicating gradual revenue growth [21] - Operating expenses for Q4 2025 were $9 million, down from $9.4 million in the prior year, showcasing disciplined expense management [19] - Net loss for Q4 2025 was $7.9 million compared to a net loss of $8.6 million in Q4 2024, demonstrating improved financial performance [21] Business Line Data and Key Metrics Changes - Research and development expenses for 2025 were $13.2 million, down from $14.7 million in 2024, as resources shifted towards commercialization [21] - Selling, general, and administrative expenses were $23.3 million in 2025, up from $21.9 million in 2024, due to targeted commercial readiness investments [21] Market Data and Key Metrics Changes - The company engaged with 13 states for partner programs, exceeding its initial goal of six states, and aims to expand to 15-17 states by year-end 2026 [8] - In Europe, the company is advancing its regulatory pathway for the preterm global test and is on track to submit European dossiers in the coming months [9] Company Strategy and Development Direction - The company aims to build evidence, access, and commercial infrastructure to drive preterm birth adoption at scale, with a focus on Medicaid and high preterm birth burden states [5] - The strategy includes launching targeted programs to generate outcomes data that support clinical adoption and reimbursement expansion [7] - The company plans to maintain disciplined investments in market access and commercial infrastructure while expanding geographically [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum gained from the PRIME publication and the growing engagement with payers and states [45] - The focus for 2026 will be on disciplined execution, advancing partner programs, and supporting clinicians in integrating PreTRM into workflows [45] - The company believes that compelling clinical evidence and increasing payer engagement will unlock significant value in an underserved market [45] Other Important Information - The company ended 2025 with $95.8 million in cash equivalents, providing a runway through 2028 for significant adoption and commercial milestones [22] - The capital allocation philosophy emphasizes disciplined deployment towards milestones that de-risk the commercial model while maintaining balance sheet strength [23] Q&A Session Summary Question: Can you expand on converting payer discussions and partner programs using outcomes and economic data? - The company highlighted the importance of clinical outcomes and economic benefits to engage partners, particularly state Medicaid agencies [29] - The reduction in NICU admissions is a significant cost driver for payers, making the economic model compelling [30] Question: What feedback was received at the SMFM conference regarding PRIME? - The conference led to increased engagement with providers and state legislators, with a focus on making the test more accessible [33] - The publication has improved credibility and engagement across various stakeholders [35] Question: How will the company balance investments in successful U.S. states versus global EU launch capital requirements? - The company plans to maintain a similar cash operating expense budget while reallocating spending towards commercial activities, including EU opportunities [39] Question: Can you elaborate on the profile of the new partner in the second partnership program? - The company is negotiating with various partners, including large health systems and provider payers, to implement the PreTRM test as standard care [41] - The second partner is an employer collaborative with multi-state opportunities, showcasing the diverse nature of partnerships [43]